Navigation Links
Galmed Pharmaceuticals Reports First Half 2014 Financial Results
Date:7/25/2014

TEL AVIV, Israel, July 25, 2014 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (Galmed), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, today announced financial results for the period ended June 30, 2014.

First Half 2014 Financial Summary:

  • Reported cash and cash equivalents totaling $37.4 million on June 30, 2014, compared with $137,000 at December 31, 2013. 
  • Reported a net loss of $3.9 million for the six months ended June 30, 2014, compared with a net loss of $1.6 million for the comparable prior year period.
  • Reported research and development expenses of $2.7 million for the six months ended June 30, 2014, compared with $1.3 million for the comparable prior year period, primarily resulting from increases in R&D subcontractor expenses and an increase in salaries and benefits due to an increase in clinical staff.
  • Reported general and administrative expenses of $1.1 million for the six months ended June 30, 2014, compared with $247,000 for the comparable prior year period, resulting from an increase in professional services and an increase in salaries and benefits, consisting of non-cash stock-based compensation and an increase in the administrative staff.
  • Reported a net loss per share of $0.42 for the six months ended June 30, 2014, compared with $0.31 per share for the comparable prior year period, in each case not taking into consideration dilution resulting from net loss during both periods.
  • Select Second Quarter 2014 and Recent Corporate Highlights:

  • Received U.S. Food and Drug Administration (FDA), clearance of the Company's Investigational New Drug application for aramchol for the treatment of fatty liver disorders,
    '/>"/>

  • SOURCE Galmed Pharmaceuticals Ltd.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
    3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
    4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
    7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
    8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
    9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
    11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... 22, 2015 Pipette.com has added the ... their comprehensive portfolio of Eppendorf products. , The Eppendorf ... a Centrifuge 5424/5424 R and receive the following:, ... Research plus or Eppendorf Reference 2 , ...
    (Date:1/22/2015)... January 22, 2015 Dr. Greg Leyer of ... annual Scripps Natural Supplements Pre-Conference seminar on probiotics in San ... an annual continuing education conference for health care professionals. This ... the topic of probiotics in health. Dr. Leyer spoke about ...
    (Date:1/22/2015)... Switzerland (PRWEB) January 22, 2015 Selexis ... characterized mammalian Research Cell Banks (RCBs) used for drug ... Research Cell Banks will include Next-Generation Sequencing ... genetic architecture de-risks biologic manufacturing by ensuring the integrity ...
    (Date:1/22/2015)... Jersey , 22 de enero de 2015  El Dr. ... hoy su llamada a nominaciones para 2015. Este prestigioso ... hecho, o tiene el potencial para hacer, contribuciones destacadas ... se aceptarán hasta el 15 de marzo de 2015 ...
    Breaking Biology Technology:Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4
    ... N.Y., Aug. 17 Emisphere,Technologies, Inc. (Nasdaq: EMIS ... sell 2.0 million shares of common stock and warrants ... purchase price of $3.785,per unit. The five-year warrants will ... of issuance at an exercise price of $3.948 per ...
    ... Sales Growth Balance of Year, SAN DIEGO, Aug. ... at the Noble Financial Equity,Conference at 11:30 a.m. EDT ... in Charleston, South Carolina. William Spencer, Imagenetix,s Chief ... science, products, and prospects for the,Company. Commenting on the ...
    ... The Foundation,for Taxpayer and Consumer Rights (FTCR) today ... fledgling Interstate Alliance for Stem Cell,Research to the public ... funded science. The decision came after a closed,session of ... Warren Wollschlager, of the Connecticut Department of Health ...
    Cached Biology Technology:Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering 2Imagenetix Inc. to Present at Noble Small Cap Financial Conference on August 21, 2007 2Consumer Advocates Praise Interstate Stem Cell Open Meeting Decision 2
    (Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
    (Date:1/22/2015)... Showcase, Hall E -   EyeLock Inc. , a market ... showcase its EyeLock ID technology integrated in a 3D printed ... Oak Ridge National Laboratory (ORNL) at the 2015 ... technology is being used to validate the driver and authorize ...
    (Date:1/22/2015)... NXTD and NXTDW) a biometric authentication company focused on ... Wocket™ smart wallet at CES 2015 in Las Vegas ... the "11 Hot Products at CES" in a review published in Wired.com, ... Newseveryday.com and "The top 10 gadgets from CES 2015" by Danny ...
    Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
    ... (FiO), the 91st Annual Meeting of the Optical Society ... San Jose, Calif., alongside Laser Science XXIII, the annual ... Science. Reporters interested in obtaining a badge to ... cmorri@osa.org . FiO RESEARCH HIGHLIGHTS ...
    ... Makes Tuna That Tastes Good, But These Bluefin Are ... bluefin tuna caught in the Gulf of Maine has ... University of New Hampshire have found by analyzing detailed ... Fishermans Co-op. The findings, published this week in Fishery ...
    ... the social habits of living cells an innovation ... help fight diseases such as cancer and diabetes. ... six countries, The Manchester Centre for Integrative Systems Biology ... research into an emerging field of science and engineering ...
    Cached Biology News:Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 2Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 3Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 4Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 5Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 6Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 7Restoring sight, advances in fertility treatments and better visibility for pilots at FIO 8Condition of bluefin tuna in gulf of maine is declining 2Condition of bluefin tuna in gulf of maine is declining 3Social habits of cells may hold key to fighting diseases 2
    human Exodus-2 Research Focus: cytokine/growth factor Storage Temperature: -20C Shipping Temperature: 4C...
    ...
    Gel Loading Buffer contains a precipitant to ensure that the samples sink into the wells and a tracking dye to allow the user to follow the progress of electrophoresis....
    Rabbit polyclonal to QKI...
    Biology Products: